Malignant mesothelioma clinical trial combines immunotherapy drugs

Immunotherapy
Monica S Chatwal, Tawee Tanvetyanon

Abstract

Immunotherapy by checkpoint inhibitor is effective for a number of solid tumors including malignant mesothelioma. Studies utilizing single-agent PD-1 or PD-L1 inhibitor for mesothelioma have reported tumor response rates in approximately 10-20% of patients treated. Given the success of combining these agents with CTLA-4 inhibitor in melanoma, there is a strong rationale to study it in mesothelioma. Recently results from clinical trials investigating this approach have been released. Though limited by small sample size, the studies conclusively demonstrated feasibility and suggested a modestly higher tumor response rate than one would expect from treatment with single-agent PD-1 or PD-L1 inhibitor. Nevertheless, toxicity was also increased. Immunotherapy-related deaths due to encephalitis, renal failure and hepatitis were observed. Further studies are warranted.

References

Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicholas J VogelzangPaolo Paoletti
Apr 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giuseppe GiacconePatrick J Loehrer
Jun 2, 2015·The New England Journal of Medicine·Dung T LeLuis A Diaz
Mar 30, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kwok F WongMichael M Hawkins
Mar 5, 2017·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Bibhusal ThapaThomas John
Sep 12, 2017·The New England Journal of Medicine·Jedd D WolchokJames Larkin
Mar 20, 2017·NPJ Precision Oncology·Feng LiuWebster K Cavenee

❮ Previous
Next ❯

Citations

Nov 27, 2018·Immunotherapy·Mike Gregg

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02899299
NCT03175172

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
Xiaoli Wei, Ruihua Xu
Critical Reviews in Oncology/hematology
Saman Maleki VarekiIgnacio Duran
© 2022 Meta ULC. All rights reserved